FOUNDER’S WORDS
“CANbridge has assembled a world class management and advisory team with the capability to select,acquire, develop and deliver promising therapeutics and diagnostics to address the severely underserved medical needs of patients in China and Asia.”
—— James Xue, Chairman & CEO
Bridging Global First-in-Class Specialty Therapies and Unmet Medical Needs in China.
ASSETS
Developing And Commercializing Top-Tier Assets From World Class Partners.
TREATMENT AREA
Covering More Than 10 Therapeutic Areas.
CLINICAL STUDY SITE
Clinical Study Sites At The Top 200 Hospitals In China.
2020.04
CANbridge Pharmaceuticals
receives marketing approval
for NERLYNX® (NERATINIB)
in China
2019.11
CANbridge Receives
Hong Kong Department
of Health Market Approval
for NERLYNX®
2019.09
CANbridge Pharmaceuticals'
hunterase® granted priority
review by the Chinese National
Medical Products Administration
2019.01
CANbridge Pharmaceuticals
and WUXi Biologics Expand
Rare Disease Therapeutics
Partnership
2019.01
CANbridge Pharmaceuticals
and GC Pharma Announce
Greater China Licensing
Agreement for Hunterase™
for Hunter Syndrome
2018.10
CANbridge Pharmaceutical
and WuXi Biologics
Enter into Strategic Partnership
for Rare Disease Therapeutics
2018.04
CANbridge Receives
Approval To Commence
CAN008 Phase II/III Trial In
GLIOBLASTOMA MULTIFORME
(GBM) In China
2018.04
CANbridge Receives
China Food and Drug
Administration Approval
For CAN002 as cancer
Adjuvant Therapy
2017.12
CANbridge Submits IND
Application for CAN017 Trial
in Esophageal Squamous
Cell Cancer.
2017.11
CANbridge Completes Patient
Enrolment for Phase I Clinical
Trial of CAN008 in Treatment
of GBM in Taiwan.
2017.09
CANbridge Appoints
Chief Business Officer,
Paul Will Head First
US Office.
2017.07
CANbridge Submits
IND Application for
CAN008 PhII/III Trial
in GBM in China.
2017.05
CANbridge Raises $25
Million in Series B
Round Led by
Lapam Capital.
2017.03
CANbridge Awarded “Deal
of The Year 2016”
by China Healthcare
Investment Conference.
